In addition to breast cancer, targeting ERβ with tamoxifen in diffuse large B-cell lymphoma (DLBCL) reduced cell viability in vitro, an effect that was significantly mitigated with knockdown of ERβ [111] and corroborated in a xenograft lymphoma model [111]. This evidence concerns the gene ESR2 and breast cancer.